Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
4
The Technology Select Sector SPDR® Fund
XLK
5
Direxion Daily Financial Bull 3X Shares ETF
FAS
CN Stock MarketDetailed Quotes
Sinocelltech Inc. (688520)
- 41.18
- -0.16-0.39%
Market Closed Apr 30 15:00 CST
19.37BMarket Cap-24.08P/E (TTM)
42.24High40.58Low2.56MlotVolume40.87Open41.34Prev Close105.98MTurnover0.58%Turnover RatioLossP/E (Static)470.34MShares89.0452wk High272.72P/B18.34BFloat Cap35.6952wk Low49.61Limit Up445.34MShs Float103.99Historical High33.07Limit Down4.02%Range %31.07Historical Low--Dividend TTM41.35Avg Price1.33MlotAsk--Div Yield TTM1Lot Size1.12MlotBid
688520 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
688520 Orderflow
Unit: --
688520 Orderflow Trend
IntradayDayWeekMonth
No Data
Sinocelltech Inc. (688520) News
Sino Cell: Sino Cell\'s First Quarter Report for 2026
Shenzhou Cell\'s First Quarter Report for 2026
Medicine Chronicles ⑦: With over 70 billion yuan in revenue, how did China create a domestic "blockbuster drug"?
① The development of China's innovative pharmaceuticals sector has indeed been rapid. In addition to antibody drugs, cutting-edge fields such as cell and gene therapy, as well as small nucleic acid drugs, are also accelerating. Based on the number of early-stage research projects and clinical pipelines, China’s innovative pharmaceutical industry is continuously catching up with mature markets in Europe and the United States, with certain sub-sectors already able to rival them; ② The core logic by which the current market evaluates innovative drugs essentially remains expanding growth potential through overseas expansion.
Sino Cell: Sino Cell 2025 Annual Report
Sino Cell: Summary of Sino Cell\'s 2025 Annual Report
Shenzhou Cell\'s 2025 Annual Report
Sinocelltech Inc. (688520) Stock Forum
Despite impressive revenue growth, the company's forecast growth is lower than the industry, not justifying its high P/S ratio. Many investors remain bullish, unwilling to sell their stock. However, unless conditions improve, the high P/S ratio is seen as unreasonable.
Subdued Growth No Barrier To Sinocelltech Group Limited's (SHSE:688520) PriceAnalysts expect Chinese Biotechs to break even in over a year, but could be delayed if growth slows. The firm's current negative equity is a significant issue.
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)